Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer
Program Introduction
CDKs 4 and 6 Are Key Regulators of Cell Growth
Current Indications for CDK4&6 Inhibitors for the Treatment of HR+/HER2-Negative Advanced or Metastatic Breast Cancer
When to Consider Adding CDK4&6 Inhibitors
Case Examples for When to Consider Adding CDK4&6 Inhibitors
Toxicity Is Currently the Primary Influencer of Choice of CDK4&6 Inhibitor
MONARCH 2 and 3 Subgroup Analysis
Other Factors Effecting Choice of CDK4&6 Inhibitors
Which CDK4&6 Inhibitor?
CDK4&6 Resistance
Managing Neutropenia
Managing Diarrhea
Quality of Life
Other Adverse Effects
Differences Between Countries
Accessibility and Funding Issues
Cyclin E1 as a Predictive Biomarker for Response to CDK4&6 Inhibitor Therapy
CDK4&6 Inhibitor Plus PI3K/AKT/mTOR Inhibitor Combination Therapy
Ongoing Challenges and Combination Strategies in Current Trials
Summary
Abbreviations
Abbreviations (cont)